For patients with cancers of unknown primary (CUP) and other diagnostically ambiguous tumors, molecular testing may help pathologists identify tumor origin and guide targeted treatment decisions, according to a new article from the College of American Pathologists (CAP).
For the full article click here: CAP Highlights Molecular Testing to Clarify Difficult-to-Classify Tumors